APRE — Aprea Therapeutics Share News
0.000.00%
Last trade - 00:00- $6.52m
- -$33.99m
- $0.29m
Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: Aprea Reports Promising Early Data for WEE1 Inhibitor in HPV+ HNSCC with MD Anderson
Aprea Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview
Aprea Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Aprea Therapeutics Inc expected to post a loss of 69 cents a share - Earnings Preview
Brief: Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc)
Brief: Aprea Therapeutics Announces Twice Daily (Bid) Dosing Of Patients In ABOYA-119 Clinical Trial Of ATRN-119 To Potentially Optimize Clinical Outcomes
Brief: Aprea Therapeutics - Got Into At The Market Offering Agreement, May Offer & Sell Shares Of Common Stock Of Up To $3 Million From Time To Time - SEC Filing
Aprea Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Aprea Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview
Aprea Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Aprea Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview
Brief: Aprea Therapeutics Announces First Patient Dosed In Phase 1 Trial Evaluating APR-1051
Aprea Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Aprea Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
Brief: Aprea Therapeutics Inc Files For Shelf Of Up To 4.4 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Aprea Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
U.S. RESEARCH ROUNDUP-Acuity Brands, CSG Systems International, Nuvation Bio